Is Emcure Pharmaceuticals Overvalued or Undervalued Right Now?
- September 1, 2026
- Posted by: Kunal Singla
- Category: Market
Emcure Pharmaceuticals CMP Rs 1,855.50 (31 Aug 2026), down 0.74%. PE 34.83 vs industry PE 38.07. ROE 18.67%. 52W range Rs 1,260.00 to Rs 2,048.00.
Quick Answer
Emcure Pharmaceuticals trades at a price to earnings ratio of 34.83 against an industry average of 38.07, which puts the stock close to fair value on a simple multiple basis rather than clearly overvalued or undervalued. The company’s 18.67% return on equity and Rs 260.97 book value per share fit broadly within its sector’s range. Whether Emcure Pharmaceuticals is overvalued or undervalued right now is less about a wide valuation gap and more about how its growth and margins evolve from here.
Is Emcure Pharmaceuticals overvalued or undervalued right now is a question worth asking given how its price to earnings ratio compares with the rest of its sector. At the current market price of Rs 1,855.50, the stock trades roughly 9.4% below its 52 week high of Rs 2,048.00 and about 47.3% above its 52 week low of Rs 1,260.00.
Emcure Pharmaceuticals’s share price moved down 0.74% in Monday’s session to Rs 1,855.50, against a market capitalisation of Rs 35,494 Cr. This article looks at the numbers, the PE ratio, price to book, return on equity, debt levels and recent earnings trends, that determine whether the current price reflects fair value or a stretched multiple.
Click Here – Get Free Investment Predictions
Emcure Pharmaceuticals Valuation Metrics: Where Does the Stock Stand?
| Valuation Metric | Emcure Pharmaceuticals |
|---|---|
| CMP (31 Aug 2026) | Rs 1,855.50 |
| Market Cap | Rs 35,494 Cr |
| P/E Ratio | 34.83 |
| Industry P/E | 38.07 |
| P/B Ratio | 7.17 |
| Sector Average P/B (pharmaceutical) | 7.31 |
| Return on Equity (ROE) | 18.67% |
| Sector Average ROE (pharmaceutical) | 12.94% |
| EPS (TTM) | Rs 53.72 |
| Book Value per Share | Rs 260.97 |
| Debt to Equity | 0.31 |
| Dividend Yield | 0.19% |
| Sector Average Dividend Yield (pharmaceutical) | 0.30% |
| 52 Week High / Low | Rs 2,048.00 / Rs 1,260.00 |
The headline number here is the price to earnings ratio. At 34.83, the Emcure Pharmaceuticals PE ratio is 0.91 times the industry average of 38.07. Measured against its pharmaceutical sector peers, the gap widens further on other measures too: a P/B of 7.17 against a sector average of 7.31, and an ROE of 18.67% against a sector average of 12.94%.
Is Emcure Pharmaceuticals Overvalued Based on Its P/E Ratio?
Based on the P/E ratio alone, Emcure Pharmaceuticals looks fairly valued. The stock’s PE of 34.83 sits close to the industry average of 38.07, which suggests the market is pricing the business roughly in line with its sector rather than at a premium or a discount. That leaves the read on whether Emcure Pharmaceuticals is overvalued or undervalued more dependent on its growth trajectory than on the PE ratio itself.
Check Emcure Pharmaceuticals’s Live Fundamentals on the Univest Screener
Emcure Pharmaceuticals’s Financial Growth and Profitability
Emcure Pharmaceuticals’s revenue moved from Rs 6,715.24 crore in FY2024 to Rs 7,968.78 crore in FY2025, a change of 18.7%. Net profit grew from Rs 527.58 crore to Rs 707.47 crore over the same period, a swing of roughly 34.1%.
The Emcure Pharmaceuticals share price has moved alongside this earnings trend, which is part of why the stock now trades at 0.91 times the industry PE of 38.07 rather than a flat multiple.
Download the Univest iOS App or Univest Android App to track Emcure Pharmaceuticals’s live share price and valuation ratios.
Arguments That Emcure Pharmaceuticals Could Be Overvalued
- High price to book: A P/B of 7.17 means the market is paying several times book value of Rs 260.97 per share.
- Low dividend yield: At 0.19%, the stock offers little income cushion if the growth story slows.
- Limited margin of safety: At Rs 1,855.50, the stock is only 9.4% below its 52 week high of Rs 2,048.00, leaving less room for error if earnings disappoint.
Arguments That Support the Premium Valuation
- High return on equity: ROE of 18.67% against a sector average of 12.94% reflects efficient use of shareholder capital.
- Low leverage: A debt to equity ratio of 0.31 gives Emcure Pharmaceuticals a comparatively strong balance sheet.
- 52 week range context: At Rs 1,855.50, the stock is 47.3% above its 52 week low of Rs 1,260.00, showing it has already found some support at lower levels.
Verdict: Is Emcure Pharmaceuticals Overvalued or Undervalued Right Now?
On balance, Emcure Pharmaceuticals looks fairly valued rather than clearly overvalued or undervalued. Its PE of 34.83 sits close to the industry average of 38.07, and its 18.67% ROE and other ratios do not point to a significant mispricing either way. The more useful question for investors from here is less about the current multiple and more about whether earnings growth accelerates or slows.
What Could Change This Valuation Picture for Emcure Pharmaceuticals?
Two broad scenarios could shift this valuation call on Emcure Pharmaceuticals in either direction. On the upside, an improvement in return ratios or growth that pushes the stock’s PE of 34.83 toward a premium over the industry average of 38.07. On the downside, a deterioration in the numbers that pulls the PE below the industry average of 38.07 instead. Investors watching the Emcure Pharmaceuticals share price over the next few quarters should track whether reported ROE holds near 18.67% and whether the PE gap versus the industry average of 38.07 widens or narrows, since both will matter more to the eventual answer than the current price point on its own.
Conclusion
Emcure Pharmaceuticals’s numbers point to a stock that is fairly valued on headline multiples. Investors tracking the Emcure Pharmaceuticals share price should watch whether earnings growth can keep pace with the current PE of 34.83, since that gap remains the single biggest variable in whether the stock is undervalued, fairly priced, or overvalued from here. This article is for informational purposes only and is not investment advice.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Emcure Pharmaceuticals Valuation
Is Emcure Pharmaceuticals overvalued or undervalued right now?
Ans. Based on a PE ratio of 34.83 against an industry average of 38.07, Emcure Pharmaceuticals currently looks fairly valued on relative valuation. Its 18.67% ROE is an important part of the picture alongside the PE ratio.
What is Emcure Pharmaceuticals’s current PE ratio?
Ans. Emcure Pharmaceuticals’s price to earnings ratio stands at 34.83, compared with an industry average PE of 38.07.
What is Emcure Pharmaceuticals’s return on equity?
Ans. Emcure Pharmaceuticals generates a return on equity of 18.67%, against a sector average of 12.94% among pharmaceutical peers.
What is Emcure Pharmaceuticals’s 52 week high and low?
Ans. Emcure Pharmaceuticals’s 52 week high is Rs 2,048.00 and its 52 week low is Rs 1,260.00. The stock currently trades around Rs 1,855.50, roughly 9.4% below its high.
Does Emcure Pharmaceuticals have high debt?
Ans. Emcure Pharmaceuticals carries a debt to equity ratio of 0.31, which is low for its sector.
What is Emcure Pharmaceuticals’s dividend yield?
Ans. Emcure Pharmaceuticals offers a dividend yield of 0.19% at the current share price.
Is Emcure Pharmaceuticals a good stock to buy at current levels?
Ans. Emcure Pharmaceuticals’s current valuation suits investors who agree with the fairly valued read on its PE ratio and are comfortable with the trade-off between its return ratios and its price. This is for informational purposes only and is not investment advice.
What is Emcure Pharmaceuticals’s price to book ratio?
Ans. Emcure Pharmaceuticals trades at a price to book ratio of 7.17, compared with a sector average of 7.31 among pharmaceutical peers.
